KYTX Strangle Strategy
KYTX (Kyverna Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
KYTX (Kyverna Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $369.6M, a beta of 1.96 versus the broader market, a 52-week range of 2.52-13.67, average daily share volume of 1.1M, a public-listing history dating back to 2024, approximately 130 full-time employees. These structural characteristics shape how KYTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.96 indicates KYTX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on KYTX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current KYTX snapshot
As of June 30, 2026, spot at $8.92, ATM IV 235.10%, IV rank 47.90%, expected move 67.40%. The strangle on KYTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this strangle structure on KYTX specifically: KYTX IV at 235.10% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 67.40% (roughly $6.01 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated KYTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on KYTX should anchor to the underlying notional of $8.92 per share and to the trader's directional view on KYTX stock.
KYTX strangle setup
The KYTX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With KYTX near $8.92, the first option leg uses a $9.37 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed KYTX chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 KYTX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $9.37 | N/A |
| Buy 1 | Put | $8.47 | N/A |
KYTX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
KYTX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on KYTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on KYTX
Strangles on KYTX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the KYTX chain.
KYTX thesis for this strangle
The market-implied 1-standard-deviation range for KYTX extends from approximately $2.91 on the downside to $14.93 on the upside. A KYTX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current KYTX IV rank near 47.90% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on KYTX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, KYTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to KYTX-specific events.
KYTX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. KYTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move KYTX alongside the broader basket even when KYTX-specific fundamentals are unchanged. Always rebuild the position from current KYTX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on KYTX?
- A strangle on KYTX is the strangle strategy applied to KYTX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With KYTX stock trading near $8.92, the strikes shown on this page are snapped to the nearest listed KYTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are KYTX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the KYTX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 235.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a KYTX strangle?
- The breakeven for the KYTX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KYTX market-implied 1-standard-deviation expected move is approximately 67.40%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on KYTX?
- Strangles on KYTX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the KYTX chain.
- How does current KYTX implied volatility affect this strangle?
- KYTX ATM IV is at 235.10% with IV rank near 47.90%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.